StockData

Vanda Pharmaceuticals vs Xeris Biopharma

VNDA and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How VNDA and XERS compare

Xeris Biopharma is the larger company, worth 13 times as much as Vanda Pharmaceuticals ($3.1B against $230M).

Xeris Biopharma grew revenue faster over the last twelve months (36.3% versus 8.1% for Vanda Pharmaceuticals).

Xeris Biopharma keeps more of each dollar of sales as profit, with a net margin of −5.1% compared with −120% at Vanda Pharmaceuticals.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricVNDAXERS
Size and price
Market cap$230M$3.1B
Share price$3.81$16.80
Change, 1 year−12.4%134%
Change, 5 years−77.0%674%
Beta (5Y)0.780.27
Employees533435
StockData Score
Total score1010
Valuation score3 (better)0
Growth score24 (better)
Performance score03 (better)
Health score5 (better)3
Dividend score00
Valuation
P/S1.0× (better)9.1×
P/B1.2×–
EV/EBITDA–84.2×
FCF yield−60.8%–
Fair value$8.53–
Margin of safety55.3%–
Growth
Revenue growth (TTM)8.1%36.3% (better)
Revenue growth, 5Y average−2.7%70.2% (better)
Profitability
Gross margin93.6% (better)86.6%
Operating margin−77.6%10.9% (better)
Net margin−120%−5.1% (better)
FCF margin−61.0%–
Return on equity−82.5%–
Return on invested capital−52.6%22.1% (better)
Financial health
Debt / equity0.00–
Net debt / EBITDA–3.45
Interest coverage–1.3×
Current ratio1.54 (better)1.45
Altman Z-score−1.853.33 (better)
Piotroski F-score38 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions82.2%59.4%
Held by insiders9.2%5.2%
Insider net buying, 12 months−$2.8M (better)−$5.8M
Short interest, % of float13.9%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.